Bonner-Weir and other scientists have argued that either the beta cells in the pancreas continue to make copies of themselves, or that the pancreatic ducts, through a process called budding or neurogenesis, continue producing new cells.
Category: Research
If you've been diagnosed with type 2 diabetes in the last 5 years, you may be eligible to help scientists test treatments by participating in an NIH study.
NIH has launched a long-term clinical trial called the GRADE study. Researchers will examine the benefits and risks of common diabetes drugs used with metformin.
The results of the AbATE clinical trial to slow the progression of type 1 diabetes have been trickling out at conferences and talks for a while now,…
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that presently available data does not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based diabetes therapies.
Great strides have been made recently in predicting who is most likely to develop type 1 diabetes, allowing researchers to identify the disease at the earliest stages of development and potentially intervene to preserve beta cell function at a much earlier stage and ultimately prevent onset of symptomatic diabetes.
This month the American Diabetes Association published the e-book edition of Targeting a Cure for Type 1 Diabetes: How Long Will We Have to Wait?…
Biodel has announced plans to submit a New Drug Application (NDA) to the FDA in 2015 for a novel glucagon rescue device to treat severe hypoglycemia.
Having previously signed a long-term commercial supply agreement for bulk glucagon, Biodel expects to select a final formulation of its novel glucagon therapy...
According to a series of study results being published in a special issue of Diabetes Care youth with type 2 diabetes experience a more rapid progression of co-morbidities far more aggressive than what is typically seen in adults, even when they receive the best currently available treatment and close monitoring of their condition.
Dr. Harrison and his team identified that some T cells express a molecule on their surfaces, CD52, that is capable of suppressing other T cells. Understanding the ways in which the immune system normally controls and suppresses T cells is crucial to our understanding what goes wrong in autoimmune diseases.
The biomaterial holding the islet cells—which is completely synthetic, is 96 percent water, and which Garcia described as having the consistency of diluted Jello-O—and that was infused into the mice, however, addresses several of these problems.